Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 90

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 90
---
 reflect the effect of the redemptions of 50% of the Public Shares; and assumes that the obligations under the Backstop Agreement will be satisfied by making a cash contribution in an amount of up to $10,000,000 to OmnigenicsAI. See “ Certain Agreements Related to the Business Combination — Backstop Agreement;” and • Scenario 3 — Assuming redemptions of 100% of outstanding Public Shares for cash: This presentation assumes that holders of Public Shares exercise their redemption rights with respect to a maximum of 100% of Public Shares upon consummation of the Business Combination at a redemption price of approximately $11.60 per share as of June30, 2024. Scenario 3 includes all adjustments contained in Scenario1, presents additional adjustments to reflect the effect of the maximum redemptions and assumes that the obligations under the Backstop Agreement will be satisfied by making a cash contribution in an amount of $10,000,000 to OmnigenicsAI, considering that there will be no remaining balance in the Trust Account remaining after payment in full of the SPAC Shareholder Redemption Amount. See “ Certain Agreements Related to the Business Combination — Backstop Agreement.” The combined financial statements of OmnigenicsAI have been prepared in accordance with IFRS as issued by the IASB and in its presentation currency of U.S. dollars. Financial information of its subsidiary, Heritas Argentina, was as translated from their respective functional currencies of Argentine Pesoin the case of OmnigenicsAI, based on the translation requirements provided for in IAS 21 “Foreign currencies.” Finally, the historical financial statements of APx have been prepared in accordance with GAAP in its functional and presentation currency of U.S. dollars. See “ Notes to Unaudited Pro Forma Combined Consolidated Financial Information — GAAP to IFRS conversion of APx’s financial information as of June 30, 2024 and for the twelve -month period ended June 30, 2023 and the six -month period ended June 30, 2024.” 17 The adjustments presented in the unaudited pro forma combined consolidated financial information have been identified and presented to provide relevant information necessary for an understanding of the Combined Company after giving effect to the Business Combination. SPAC and OmnigenicsAI, and its subsidiary, did not have any intercompany transactions prior to the Business Combination. Accordingly, no pro forma adjustments were required to eliminate activities between the companies. See to “ Certain APx Relationships and Related Person